Latest Rituximab Stories
Marketing Strategies That Educate Payers and Prescribers on Key Benefits of New Drugs Will Maximize Rapid Formulary Inclusion, According to Findings from Decision Resources Group BURLINGTON,
Achieve is conducting a multicenter, randomized, single-dose study assessing the pharmacodynamic parameters of an experimental combination therapy in
Public Healthcare Systems in Brazil and Mexico Cover Targeted Therapies but with Indication-Specific Restrictions, According to Findings from Decision Resources Group BURLINGTON, Mass., June
- Data include results from two Phase I studies of ABT-199/GDC-0199 in relapsed/refractory chronic lymphocytic leukemia (CLL) and various subtypes of non-Hodgkin's lymphoma (NHL) NORTH
- The long-term safety profile was consistent with pivotal trials of Cimzia® ATLANTA, May 5, 2014 /PRNewswire/ -- UCB announced today results from the PRECiSE 3 7-year open label extension
First full quarter after launch of IMBRUVICA(TM) net product revenue of $56.2 million SUNNYVALE, Calif., May 2, 2014 /PRNewswire/ -- Pharmacyclics, Inc.
Rheumatologists Cite Improved Health-Related Quality of Life, Improved Effect in Disease Activity among Unmet Needs, According to Findings from Decision Resources Group BURLINGTON, Mass., April
SUNNYVALE, Calif., April 21, 2014 /PRNewswire/ -- Pharmacyclics, Inc.
Emerging Therapies are Not Expected to Offer Improvements in Safety and Tolerability Attributes, According to Findings from Decision Resources Group BURLINGTON, Mass., April 10, 2014 /PRNewswire/
MabThera SC offers a faster administration time for patients in Europe while potentially saving valuable time for health systems SAN DIEGO, March 28, 2014 /PRNewswire/ -- Halozyme
- The deadly nightshade, Atropa Belladonna, which possesses stupefying or poisonous properties.
- A sleeping-potion; a soporific.
- To mutter deliriously.